TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32977015

Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming (RAP)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional priming
Number of subjects: 124
Study: 36314123

Group type: EXPERIMENTAL
Intervention: TASC (Telehealth After Stroke Care)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 33259725

Group type: EXPERIMENTAL
Intervention: Tinnitus Counseling (TC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized Tinnitus Retraining Therapy (TRT)
Number of subjects: 0
Study: 33096193

Group type: EXPERIMENTAL
Intervention: ProTaper NEXT (PTN)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ProTaper Gold (PTG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: WaveOne Gold (WOG)
Number of subjects: 24
Study: 35922107

Group type: EXPERIMENTAL
Intervention: Suchana intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33247085

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 12019

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 12019
Study: 33831327

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (200 micrograms, orally administered, 4 times daily for 8 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Number of subjects: 36
Study: 32600942

Group type: EXPERIMENTAL
Intervention: Freeze-only strategy
Number of subjects: 5155

Group type: COMPARATOR
Intervention: Fresh embryo transfer
Number of subjects: 5155
Study: 34924224

Group type: EXPERIMENTAL
Intervention: Guided imagery (four sessions over four consecutive days using headphones)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no guided imagery)
Number of subjects: 70
Study: 33559019

Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment (PRT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 44
Study: 32094516

Group type: EXPERIMENTAL
Intervention: Hybrid-FES rowing (n=10), 6 months, 3 times per week, 70-85% of maximal heart rate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard of care (n=15), either arm ergometer exercise (n=6) or waitlist (n=9)
Number of subjects: 25
Study: 34695400

Group type: EXPERIMENTAL
Intervention: ERF-free patients (n = 1051)
Number of subjects: 1417

Group type: COMPARATOR
Intervention: ERF patients (n = 366)
Number of subjects: 1417
Study: 34271853

Group type: EXPERIMENTAL
Intervention: Hydromorphone hydrochloride 0.1 mg/kg (H1)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Hydromorphone hydrochloride 0.2 mg/kg (H2)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Sufentanil 1.5 µg/kg (S)
Number of subjects: 222
Study: 35984658

Group type: EXPERIMENTAL
Intervention: Surveillance endoscopy between 9 and 15 months after index endoscopy
Number of subjects: 4523

Group type: COMPARATOR
Intervention: Index endoscopy using white light and narrow-band imaging
Number of subjects: 4523

Group type: EXPERIMENTAL
Intervention: Surveillance endoscopy for patients with early GC detected during index endoscopy
Number of subjects: 4523

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of risk factors
Number of subjects: 4523
Study: 34459239

Group type: EXPERIMENTAL
Intervention: Factor V Leiden carriers
Number of subjects: 17623
Study: 35296141

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 33099662

Group type: EXPERIMENTAL
Intervention: Siderophore-producing microorganisms (SPMs) including Sinorhizobium meliloti, Pseudomonas fluorescence, and P. indica
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: P. fluorescens and P. indica (alone or in combination)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Siderophore-producing microorganisms (SPMs)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: P. indica (alone or in combination with SPB)
Number of subjects: 3
Study: 32729888

Group type: COMPARATOR
Intervention: Ranibizumab, 0.5 mg every 4 weeks (arm A)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Faricimab, 1.5 mg every 4 weeks (arm B)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Faricimab, 6.0 mg every 4 weeks (arm C)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Faricimab, 6.0 mg every 4 weeks until week 12, then faricimab, 6.0 mg every 8 weeks (arm D)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Ranibizumab, 0.5 mg every 4 weeks until week 8, then faricimab, 6.0 mg every 4 weeks (arm E)
Number of subjects: 263
Study: 36063545

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 0
Study: 33725857

Group type: EXPERIMENTAL
Intervention: Yiqi Liangxue Shengji prescription (YLS)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: YLS
Number of subjects: 140

Group type: COMPARATOR
Intervention: YLS placebo
Number of subjects: 140
Study: 32080013

Group type: EXPERIMENTAL
Intervention: AttraX® Putty
Number of subjects: 100

Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 100
Study: 33471115

Group type: EXPERIMENTAL
Intervention: Deep learning model for quantifying percent global glomerulosclerosis
Number of subjects: 83

Group type: COMPARATOR
Intervention: On-call pathologists' estimates of percent global glomerulosclerosis
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Deep learning model with pooled glomeruli counts from multiple levels
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Deep learning model
Number of subjects: 83
Study: 34587719

Group type: EXPERIMENTAL
Intervention: Acalabrutinib monotherapy (oral, total daily doses of 100-400 mg, later switched to 100 mg twice daily)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Acalabrutinib monotherapy
Number of subjects: 762
Study: 35362456

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 32
Study: 33415555

Group type: EXPERIMENTAL
Intervention: Nebulized isotonic magnesium (1024 mg/h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous magnesium (200 mg/kg over 30 min, followed by 50 mg/kg/h)
Number of subjects: 28
Study: 35290431

Group type: EXPERIMENTAL
Intervention: Videoconference training
Number of subjects: 41

Group type: COMPARATOR
Intervention: Face-to-face training
Number of subjects: 41
Study: 33410261

Group type: EXPERIMENTAL
Intervention: Systemic immune-inflammation index (SII)
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: pTNM stage
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Platelet–lymphocyte ratio (PLR)
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Nomogram model for predicting 5-year prognosis
Number of subjects: 852
Study: 32320171

Group type: EXPERIMENTAL
Intervention: Alternate nostril breathing (ANB) exercise for 10 min/day over 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 34530112

Group type: EXPERIMENTAL
Intervention: 30 g/d of 85% cocoa chocolate (DC85)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 70% cocoa chocolate (DC70)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No chocolate (control group, CON)
Number of subjects: 48
Study: 34635353

Group type: EXPERIMENTAL
Intervention: Enzyme alginogel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Copper and zinc chelate gel (coppergel)
Number of subjects: 0
Study: 36114615

Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: DASH diet plus physical activity (DASHPED)
Number of subjects: 35
Study: 33428746

Group type: EXPERIMENTAL
Intervention: CrashCourse (CC)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Centers for Disease Control (CDC) video educational materials (Vi)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CDC written educational materials (Wr)
Number of subjects: 118
Study: 32879890

Group type: EXPERIMENTAL
Intervention: Nordic Musculoskeletal Questionnaire (NMQ‐E)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Dutch Musculoskeletal Questionnaire (DMQ)
Number of subjects: 207
Study: 34091935

Group type: EXPERIMENTAL
Intervention: Individual-level intervention (counseling)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Building-level intervention
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Building-level intervention followed by individual intervention
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Individual-level intervention followed by building intervention
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 331

Group type: COMPARATOR
Intervention: Building-level intervention after individual intervention
Number of subjects: 331
Study: 33840773

Group type: EXPERIMENTAL
Intervention: Varenicline (up to 2 mg daily)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 33955479

Group type: EXPERIMENTAL
Intervention: Nocturnal wear of dentures
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nocturnal nonwear of dentures
Number of subjects: 77
Study: 32653571

Group type: EXPERIMENTAL
Intervention: Brain MRI/S after 24 vs. 72 hours of hypothermia
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: T2 brain lesions in the lentiform nuclei
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lactate and NAA concentrations
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: MRI/S biomarkers
Number of subjects: 23
Study: 33999270

Group type: EXPERIMENTAL
Intervention: Dignity therapy (N = 32)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (N = 34)
Number of subjects: 66
Study: 35366050

Group type: EXPERIMENTAL
Intervention: Risk best practice communication strategy
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Emotional support communication strategy
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Teach-back communication strategy
Number of subjects: 1017

Group type: COMPARATOR
Intervention: Basic condition (control)
Number of subjects: 1017
Study: 33581727

Group type: EXPERIMENTAL
Intervention: Penehyclidine
Number of subjects: 218

Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 218
Study: 36327627

Group type: EXPERIMENTAL
Intervention: Multimodal exercise program (aerobic exercise, resistance exercise, and pelvic floor muscle training)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) only
Number of subjects: 33
Study: 34717765

Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived stem cells (ADSCs) ELIXCYTE®
Number of subjects: 57

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 57
Study: 32112496

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT) for 14 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Unstructured group meetings
Number of subjects: 75
Study: 616625620

Group type: EXPERIMENTAL
Intervention: Ginseng extract (300 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 36085339

Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 33001324

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical tibial nerve stimulation (TTNS)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Sham electrical stimulation
Number of subjects: 340
Study: 35024710

Group type: EXPERIMENTAL
Intervention: Whole chickpeas
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Chickpea puree
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Chickpea pasta
Number of subjects: 13

Group type: COMPARATOR
Intervention: Mashed potato (control)
Number of subjects: 13
Study: 33230640

Group type: EXPERIMENTAL
Intervention: Self-kindness to the mind condition
Number of subjects: 90

Group type: COMPARATOR
Intervention: Self-kindness to the mind and body condition
Number of subjects: 90
Study: 32438024

Group type: EXPERIMENTAL
Intervention: Trial participants with structured diabetes-specific education; specific intervention details not provided.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original RCT findings; specific intervention details not provided.
Number of subjects: 0
Study: 34412166

Group type: EXPERIMENTAL
Intervention: 15 mg pure CBD
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 300 mg pure CBD
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 1500 mg pure CBD
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 33745898

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy (IMT) including high-intensity statins and ACE-I or ARB
Number of subjects: 4422

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 4422

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy (IMT)
Number of subjects: 4422
Study: 34599507

Group type: EXPERIMENTAL
Intervention: Video-based demonstration
Number of subjects: 46

Group type: COMPARATOR
Intervention: Slide-based demonstration
Number of subjects: 46
Study: 34323929

Group type: EXPERIMENTAL
Intervention: Web app‐based music listening intervention delivered via headphones
Number of subjects: 311

Group type: COMPARATOR
Intervention: Noise‐canceling headphones without music (Control)
Number of subjects: 311
Study: 35150246

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 575

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study: 33601731

Group type: EXPERIMENTAL
Intervention: Active Interpretation Bias Training (IBT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline learning rate
Number of subjects: 50
Study: 32602261

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided cyanoacrylate obturation (EUS-CYA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard of care (EGD-CYA)
Number of subjects: 30
Study: 34922314

Group type: EXPERIMENTAL
Intervention: Non-sedation
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Non-sedation failure
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Non-sedation success
Number of subjects: 700

Group type: COMPARATOR
Intervention: Light sedation
Number of subjects: 700
Study: 33811557

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 42
Study: 35732378

Group type: EXPERIMENTAL
Intervention: Enhanced training for cognitive behavioural therapists
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard treatment by IAPT therapists
Number of subjects: 600
Study: 32000046

Group type: EXPERIMENTAL
Intervention: Positive Scapular Assistance Test (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Negative Scapular Assistance Test (n = 25)
Number of subjects: 50
Study: 35395801

Group type: EXPERIMENTAL
Intervention: RPE
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MARPE
Number of subjects: 40
Study: 33617061

Group type: EXPERIMENTAL
Intervention: FLY
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: NHE
Number of subjects: 27
Study: 33150715

Group type: EXPERIMENTAL
Intervention: Hydralazine–isosorbide dinitrate (H-ISDN)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 44
Study: 34838156

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily plus trametinib 2 mg once daily orally
Number of subjects: 58
Study: 33441702

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no probiotics)
Number of subjects: 80
Study: 35808375

Group type: EXPERIMENTAL
Intervention: WAT-based exercise training (ET) program, 1 year, three times per week
Number of subjects: 42
Study: 32350790

Group type: EXPERIMENTAL
Intervention: Observation Schedule for Children with Autism-Anxiety, Behaviour and Parenting (OSCA-ABP)
Number of subjects: 83
Study: 33031860

Group type: EXPERIMENTAL
Intervention: Standard SMR training session with positive expectancy (placebo condition)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard SMR training session with negative expectancy (nocebo condition)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard SMR training session with no expectancy (no-expectancy condition)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard SMR training session
Number of subjects: 30
Study: 32654804

Group type: COMPARATOR
Intervention: Standard digital mammography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tomosynthesis mammography
Number of subjects: 0
Study: 34289443

Group type: EXPERIMENTAL
Intervention: Auricular acupressure using vaccaria seeds
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo auricular acupressure using vaccaria seeds
Number of subjects: 54
Study: 32085669

Group type: EXPERIMENTAL
Intervention: Trastuzumab-based neoadjuvant therapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Trastuzumab-based neoadjuvant therapy with ct-miR-148a and ct-miR-140-5p
Number of subjects: 52
Study: 36064284

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) treatment
Number of subjects: 90
Study: 33135865

Group type: EXPERIMENTAL
Intervention: Ertugliflozin/metformin FDC tablet (2.5/500 mg or 7.5/850 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Canadian-sourced metformin coadministered with ertugliflozin
Number of subjects: 32
Study: 33372542

Group type: EXPERIMENTAL
Intervention: 30SMA-P (using social networks on a smartphone prior to exercise)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SMA-INT (using social networks on a smartphone intra-session)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON (watching TV before exercise)
Number of subjects: 12
Study: 32893063

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 0
Study: 36333268

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily) and Savolitinib (300 mg twice daily)
Number of subjects: 44
Study: 33428358

Group type: EXPERIMENTAL
Intervention: CBRNe PPE
Number of subjects: 36

Group type: COMPARATOR
Intervention: No PPE
Number of subjects: 36
Study: 32521448

Group type: EXPERIMENTAL
Intervention: Website designs with risk indicators
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Website designs grouping chemicals with harms
Number of subjects: 1441
Study: 36120338

Group type: EXPERIMENTAL
Intervention: Maxing Ganshi Decoction (MGD)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 33399541

Group type: EXPERIMENTAL
Intervention: Activity Tracker (AT) with text message feedback from an accredited exercise physiologist (AEP)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Telephone Counseling (TC) with phone calls from an AEP
Number of subjects: 117

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Activity Tracker (AT)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Telephone Counseling (TC)
Number of subjects: 117
Study: 35392336

Group type: EXPERIMENTAL
Intervention: Education based on Kolb's learning style (four 45 minutes sessions, two sessions per week)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group received the same educational content presented with a lecture and a booklet
Number of subjects: 62
Study: 33382752

Group type: EXPERIMENTAL
Intervention: COVID-19 impact assessment
Number of subjects: 52
Study: 34767869

Group type: EXPERIMENTAL
Intervention: Deucravacitinib (selective TYK2 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33974621

Group type: EXPERIMENTAL
Intervention: Community-led HIV self-testing (HIVST)
Number of subjects: 7920
Study: 34620570

Group type: EXPERIMENTAL
Intervention: Ultrasound-based endovascular renal denervation (RDN)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: CTA or MRA imaging
Number of subjects: 324
Study: 33887241

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 μg)
Number of subjects: 1674

Group type: COMPARATOR
Intervention: Slow-release dinoprostone pessary (10 μg)
Number of subjects: 1674
Study: 32901242

Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender fragrance during IANB
Number of subjects: 46

Group type: COMPARATOR
Intervention: IANB without fragrance
Number of subjects: 46
Study: 35952956

Group type: EXPERIMENTAL
Intervention: Non-Pneumatic Compression Device (NPCD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Active Pneumatic Compression Device (APCD)
Number of subjects: 50
Study: 33476803

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg, intravenous, every 2 weeks for ≤12 months)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study: 32851060

Group type: EXPERIMENTAL
Intervention: Adapted Rhythmic Gymnastics (ARG) program, 16 weeks, 3 sessions per week, 50 minutes each session
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional control group
Number of subjects: 22
Study: 35776879

Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walking Test (ISWT)
Number of subjects: 26
Study: 32731478

Group type: EXPERIMENTAL
Intervention: Apple beverage (234 mg flavanols)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Coffee berry beverage (440 mg chlorogenic acid)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Blueberry beverage (300 mg anthocyanins)
Number of subjects: 32
Study: 34050269

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (HT) at 33.5°C for 1-25 hours (n=6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normothermia (NT) (n=6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (HT)
Number of subjects: 12
Study: 33573926

Group type: EXPERIMENTAL
Intervention: 2 mg/kg methylprednisolone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stress-dose corticosteroid (SDC) regimen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35692065

Group type: EXPERIMENTAL
Intervention: Oral prednisone acetate group (n=28)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined with local injection Triamcinolone acetonide group (n=30)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (n=23)
Number of subjects: 81